Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.
종목 코드 EW
회사 이름Edwards Lifesciences Corp
상장일Mar 27, 2000
CEOMr. Bernard J. Zovighian
직원 수15800
유형Ordinary Share
회계 연도 종료Mar 27
주소One Edwards Way
도시IRVINE
증권 거래소NYSE Consolidated
국가United States of America
우편 번호92614
전화19492502500
웹사이트https://www.edwards.com
종목 코드 EW
상장일Mar 27, 2000
CEOMr. Bernard J. Zovighian
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음